Santhera Pharmaceuticals hits the market with Sfr77m capital raising

Santhera Pharmaceuticals, the Swiss speciality pharmaceuticals company, has launched a Sfr77m fundraising following the release of its latest earnings statement on Wednesday morning.

  • By Aidan Gregory
  • 12 Dec 2018

UBS is bookrunner on the accelerated bookbuild, which consists of up to 5m new shares.

 Shares in Santhera are down 67% over the past 12 months, and hit a new 52-week low on Tuesday after falling 10% in during morning trading.

The Sfr77m to be raised is ...

Please take a trial or subscribe to access this content.

Contact our subscriptions team to discuss your access: subs@globalcapital.com

Corporate access

To discuss GlobalCapital access for your entire department or company please contact our subscriptions sales team at: subs@globalcapital.com or find out more online here.

All International Bonds

Rank Lead Manager Amount $m No of issues Share %
  • Last updated
  • Today
1 JPMorgan 134,743.10 557 8.28%
2 Citi 127,287.75 499 7.83%
3 Bank of America Merrill Lynch 106,110.85 421 6.52%
4 Barclays 101,992.87 397 6.27%
5 Deutsche Bank 82,349.11 329 5.06%

Bookrunners of All Syndicated Loans EMEA

Rank Lead Manager Amount $m No of issues Share %
  • Last updated
  • Today
1 Bank of America Merrill Lynch 11,525.35 30 7.19%
2 BNP Paribas 8,639.54 48 5.39%
3 UniCredit 8,606.13 45 5.37%
4 Deutsche Bank 8,298.69 30 5.18%
5 Commerzbank Group 7,837.68 40 4.89%

Bookrunners of all EMEA ECM Issuance

Rank Lead Manager Amount $m No of issues Share %
  • Last updated
  • Today
1 Morgan Stanley 4,430.39 19 11.21%
2 Goldman Sachs 4,006.06 15 10.14%
3 Citi 3,532.95 22 8.94%
4 JPMorgan 2,809.08 19 7.11%
5 UBS 2,241.39 12 5.67%